| 000 | 01829cam a2200337 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030341.0 | ||
| 008 | 110124s2010 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.08.08.M.Sc.2010.Ah.P | ||
| 100 | 0 | _aAhmed Adel Mohamed Alaa Eldin | |
| 245 | 1 | 2 |
_aA pharmaceutical study on certain modified release etodolac dosage forms / _cAhmed Adel Mohamed Alaa Eldin ; Supervised Ahmed Abdelbary Abdelrahman , Mina Ibrahim Tadros |
| 246 | 1 | 5 | _aدراسة صيدلية على بعض الأشكال الصيدلية محورة الأنطلاق لعقار الإيتودولاك |
| 260 |
_aCairo : _bAhmed Adel Mohamed Alaa Eldin , _c2010 |
||
| 300 |
_a200 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics | ||
| 520 | _aEtodolac is non - steroidal anti - inflammatory drug acting by a preferential inhibition of cyclo - oxygenase - 2 ( COX - 2 ) enzyme . It is used for rheumatoid arthritis , including juvenile idiopathic arthritis , osteoathritis and for the treatment of acute pain . It has an elimination half - life of 7 hour and the recommended oral dose , 200 to 400 mg, is given every 6 to 8 hours to a maximum of 1.2 g daily , therefore it is a potential cadidate for controlled release formulations | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aControlled porosity osmotic pump ( CPOP ) tablets | |
| 653 | 4 | _aControlled release lipid matrix tablets | |
| 653 | 4 | _aEtodolac | |
| 700 | 0 |
_aAhmed Abdelbary Abdelrahman , _eSupervisor |
|
| 700 | 0 |
_aMina Ibrahim Tadros , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aFatma _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c32869 _d32869 |
||